About: Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice
Creator	Fukushi, Shuetsu Morimoto, Kinjiro Yoshikawa, Tomoki Fujii, Hikaru Harada, Shizuko Horiya, Madoka Iizuka-Shiota, Itoe Inagaki, Takuya Lim, Chang-Kweng Satoh, Masaaki Shibamura, Miho Yamada, Souichi Id, Kato Id, Hirofumi Mutsuyo, Takayama-Ito Posadas-Herrera Id, Guillermo Saijo Id, Masayuki
Source	Medline; PMC
abstract	Middle East respiratory syndrome-coronavirus (MERS-CoV) is an emerging virus that causes severe disease with fatal outcomes; however, there are currently no approved vaccines or specific treatments against MERS-CoV. Here, we developed a novel bivalent vaccine against MERS-CoV and rabies virus (RV) using the replication-incompetent P-gene-deficient RV (RVΔP), which has been previously established as a promising and safe viral vector. MERS-CoV spike glycoprotein comprises S1 and S2 subunits, with the S1 subunit being a primary target of neutralizing antibodies. Recombinant RVΔP, which expresses S1 fused with transmembrane and cytoplasmic domains together with 14 amino acids from the ectodomains of the RV-glycoprotein (RV-G), was developed using a reverse genetics method and named RVΔP-MERS/S1. Following generation of RVΔP-MERS/S1 and RVΔP, our analysis revealed that they shared similar growth properties, with the expression of S1 in RVΔP-MERS/S1-infected cells confirmed by immunofluorescence and western blot, and the immunogenicity and pathogenicity evaluated using mouse infection experiments. We observed no rabies-associated signs or symptoms in mice inoculated with RVΔP-MERS/S1. Moreover, virus-specific neutralizing antibodies against both MERS-CoV and RV were induced in mice inoculated intraperitoneally with RVΔP-MERS/S1. These findings indicate that RVΔP-MERS/S1 is a promising and safe bivalent-vaccine candidate against both MERS-CoV and RV.
has issue date	2019-10-07(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0223684
bibo:pmid	31589656
has license	cc-by
sha1sum (hex)	cf12680358351109a975a23165bbb48620b578a5
schema:url	https://doi.org/10.1371/journal.pone.0223684
resource representing a document's title	Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice
has PubMed Central identifier	PMC6779238
has PubMed identifier	31589656
schema:publication	PLoS One
resource representing a document's body	covid:cf12680358351109a975a23165bbb48620b578a5#body_text
is schema:about of	named entity 'RABIES VIRUS' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'confirmed' named entity 'MERS-CoV' named entity 'recombinant' covid:arg/cf12680358351109a975a23165bbb48620b578a5 named entity 'MERS-COV' named entity 'SUBUNIT' named entity 'CELLS' named entity 'WESTERN BLOT' named entity 'OUR' named entity 'SEVERE DISEASE' named entity 'CURRENTLY' named entity 'ESTABLISHED' named entity 'OBSERVED' named entity 'VIRUS' named entity 'PROPERTIES' named entity 'CYTOPLASMIC' named entity 'GENERATION' named entity 'TRANSMEMBRANE' named entity 'IS A' named entity 'SHARED' named entity 'EXPERIMENTS' named entity 'NAMED' named entity 'FOLLOWING' named entity 'TARGET' named entity 'RABIES' named entity 'GROWTH' named entity 'VACCINES' named entity 'BEING' named entity 'IMMUNOFLUORESCENCE' named entity 'PREVIOUSLY' named entity 'REPLICATION' named entity 'INFECTION' named entity 'EXPRESSION' named entity 'SIGNS OR SYMPTOMS' named entity 'SAFE' named entity 'VACCINE CANDIDATE' named entity 'MERS-COV' named entity 'REPLICATION' named entity 'CAUSES' named entity 'IMMUNOGENICITY' named entity 'PATHOGENICITY' named entity 'NOVEL' named entity 'INDUCED' named entity 'TREATMENTS' named entity 'MIDDLE EAST RESPIRATORY SYNDROME' named entity 'FATAL OUTCOMES' named entity 'HERE' named entity 'DEVELOPMENT' named entity 'DEFICIENT' named entity 'MICE' named entity 'SIMILAR' named entity 'THESE' named entity 'NEUTRALIZING ANTIBODIES' named entity 'MOUSE' named entity 'IMMUNOGENICITY' named entity 'RECOMBINANT' named entity 'MICE' named entity 'VACCINE' named entity 'RABIES VIRUS' named entity 'FINDINGS' named entity 'VACCINE' named entity 'ASSOCIATED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software